Chronic Myelomonocytic Leukemia: Focus on Clinical Practice

Mayo Clinic Proceedings

Volumn 91, Issue 2, 2016, Pages 259-272

  Patnaik, Mrinal M ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AG 120; AG 881; AZACITIDINE; CYTARABINE; DECITABINE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; ELTROMBOPAG; ENASIDENIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; HYDROXYUREA; ISOCITRATE DEHYDROGENASE INHIBITOR; LENALIDOMIDE; LONAFARNIB; LUSPATERCEPT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PANOBINOSTAT; PLACEBO; PRACINOSTAT; RECOMBINANT ERYTHROPOIETIN; RETINOIC ACID; RUBITECAN; RUXOLITINIB; SOTATERCEPT; TIPIFARNIB; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; ANTINEOPLASTIC AGENT; ASXL1 PROTEIN, HUMAN; REPRESSOR PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; AGRANULOCYTOSIS; ALLOGENEIC STEM CELL TRANSPLANTATION; ASXL1 GENE; ATYPICAL CHRONIC MYELOID LEUKEMIA; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CANCER PROGNOSIS; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL (TOPIC); CYTOGENETICS; CYTOPENIA; DIFFERENTIAL DIAGNOSIS; DRUG RESEARCH; FLOW CYTOMETRY; GASTROINTESTINAL DISEASE; GENE MUTATION; GRAFT VERSUS HOST REACTION; HEARING IMPAIRMENT; HUMAN; IMMUNOPHENOTYPING; IRON CHELATION; IRON OVERLOAD; JUVENILE MYELOMONOCYTIC LEUKEMIA; KIDNEY FAILURE; LIVER FAILURE; LOW DRUG DOSE; MEDICAL DECISION MAKING; MONOCYTOSIS; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; OFF LABEL DRUG USE; ONCOGENE; ONCOGENE RAS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REVIEW; RISK ASSESSMENT; SRSF2 GENE; TET2 GENE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL IMPAIRMENT; ALLOTRANSPLANTATION; CELL TRANSFORMATION; DISEASE MANAGEMENT; GENETICS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MEDICATION THERAPY MANAGEMENT; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; PROCEDURES; PROGNOSIS; STEM CELL TRANSPLANTATION; TRENDS;

ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DIAGNOSIS, DIFFERENTIAL; DISEASE MANAGEMENT; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MEDICATION THERAPY MANAGEMENT; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; PROGNOSIS; REPRESSOR PROTEINS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84974733258     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2015.11.011     Document Type: Review

References (95)

1. 1 Patnaik, M.M., Parikh, S.A., Hanson, C.A., Tefferi, A., Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. Br J Haematol 165:3 (2014), 273–286.
2. 2 Swederlow, S.H., Campo, E., Harris, N.L., et al. (eds.) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed., 2008, International Agency for Research on Cancer, Lyon, France.
3. 3 Adès, L., Sekeres, M.A., Wolfromm, A., et al. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res 37:6 (2013), 609–613.
4. 4 Patnaik, M.M., Lasho, T.L., Finke, C.M., et al. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Am J Hematol 88:3 (2013), 201–206.
5. 5 Such, E., Germing, U., Malcovati, L., et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood 121:15 (2013), 3005–3015.
6. 6 Williamson, P.J., Kruger, A.R., Reynolds, P.J., Hamblin, T.J., Oscier, D.G., Establishing the incidence of myelodysplastic syndrome. Br J Haematol 87:4 (1994), 743–745.
7. 7 Rollison, D.E., Howlader, N., Smith, M.T., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 112:1 (2008), 45–52.
8. 8 Takahashi, K., Pemmaraju, N., Strati, P., et al. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood 122:16 (2013), 2807–2811.
9. 9 Subari, S., Patnaik, M., Alfakara, D., et al. Patients with therapy-related CMML have shorter median overall survival than those with de novo CMML: Mayo Clinic long-term follow-up experience. Clin Lymphoma Myeloma Leuk 15:9 (2015), 546–549.
10. 10 Bennett, J.M., Catovsky, D., Daniel, M.T., et al. Proposals for the classification of the acute leukaemias: French-American-British (FAB) Co-operative Group. Br J Haematol 33:4 (1976), 451–458.
11. 11 Mathew, R.A., Bennett, J.M., Liu, J.J., et al. Cutaneous manifestations in CMML: indication of disease acceleration or transformation to AML and review of the literature. Leuk Res 36:1 (2012), 72–80.
12. 12 Patnaik, M.M., Wassie, E.A., Lasho, T.L., Hanson, C.A., Ketterling, R., Tefferi, A., Blast transformation in chronic myelomonocytic leukemia: risk factors, genetic features, survival, and treatment outcome. Am J Hematol 90:5 (2015), 411–416.
13. 13 Elliott, M.A., Verstovsek, S., Dingli, D., et al. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res 31:11 (2007), 1503–1509.
14. 14 Onida, F., Kantarjian, H.M., Smith, T.L., et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 99:3 (2002), 840–849.
15. 15 Patnaik, M.M., Itzykson, R., Lasho, T.L., et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia 28:11 (2014), 2206–2212.
16. 16 Patnaik, M.M., Padron, E., LaBorde, R.R., et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia 27:7 (2013), 1504–1510.
17. 17 Itzykson, R., Kosmider, O., Renneville, A., et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 31:19 (2013), 2428–2436.
18. 18 Druker, B.J., Guilhot, F., O'Brien, S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:23 (2006), 2408–2417.
19. 19 Apperley, J.F., Gardembas, M., Melo, J.V., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347:7 (2002), 481–487.
20. 20 Pardanani, A., Ketterling, R.P., Li, C.Y., et al. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 30:8 (2006), 965–970.
21. 21 Tefferi, A., Gilliland, D.G., Oncogenes in myeloproliferative disorders. Cell Cycle 6:5 (2007), 550–566.
22. 22 Selimoglu-Buet, D., Wagner-Ballon, O., Saada, V., et al. Francophone Myelodysplasia Group. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood 125:23 (2015), 3618–3626.
23. 23 Ziegler-Heitbrock, L., Ancuta, P., Crowe, S., et al. Nomenclature of monocytes and dendritic cells in blood. Blood 116:16 (2010), e74–e80.
24. 24 Bain, B.J., What is a promonocyte?. Am J Hematol, 88(10), 2013, 919.
25. 25 Such, E., Cervera, J., Costa, D., et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica 96:3 (2011), 375–383.
26. 26 Tang, G., Zhang, L., Fu, B., et al. Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. Am J Hematol 89:8 (2014), 813–818.
27. 27 Wassie, E.A., Itzykson, R., Lasho, T.L., et al. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study. Am J Hematol 89:12 (2014), 1111–1115.
28. 28 McCullough, K.B., Patnaik, M.M., Chronic myelomonocytic leukemia: a genetic and clinical update. Curr Hematol Malig Rep 10:3 (2015), 292–302.
29. 29 Itzykson, R., Kosmider, O., Renneville, A., et al. Clonal architecture of chronic myelomonocytic leukemias. Blood 121:12 (2013), 2186–2198.
30. 30 Abdel-Wahab, O., Pardanani, A., Patel, J., et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 25:7 (2011), 1200–1202.
31. 31 Balasubramani, A., Larjo, A., Bassein, J.A., et al. Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex. Nat Commun, 6, 2015, 7307.
32. 32 Abdel-Wahab, O., Adli, M., LaFave, L.M., et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 22:2 (2012), 180–193.
33. 33 Yamazaki, J., Taby, R., Vasanthakumar, A., et al. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics 7:2 (2012), 201–207.
34. 34 Abdel-Wahab, O., Levine, R.L., Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood 121:18 (2013), 3563–3572.
35. 35 Abdel-Wahab, O., Mullally, A., Hedvat, C., et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114:1 (2009), 144–147.
36. 36 Ko, M., Huang, Y., Jankowska, A.M., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468:7325 (2010), 839–843.
37. 37 Figueroa, M.E., Lugthart, S., Li, Y., et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17:1 (2010), 13–27.
38. 38 Meggendorfer, M., Roller, A., Haferlach, T., et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 120:15 (2012), 3080–3088.
39. 39 Patnaik, M.M., Lasho, T.L., Hodnefield, J.M., et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 119:2 (2012), 569–572.
40. 40 Yoshida, K., Sanada, M., Shiraishi, Y., et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478:7367 (2011), 64–69.
41. 41 Kohlmann, A., Grossmann, V., Klein, H.U., et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 28:24 (2010), 3858–3865.
42. 42 Ricci, C., Fermo, E., Corti, S., et al. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clin Cancer Res 16:8 (2010), 2246–2256.
43. 43 Kuo, M.C., Liang, D.C., Huang, C.F., et al. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia 23:8 (2009), 1426–1431.
44. 44 Padron, E., Garcia-Manero, G., Patnaik, M.M., et al. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J, 5, 2015, e333.
45. 45 Greenberg, P.L., Tuechler, H., Schanz, J., et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood 120:12 (2012), 2454–2465.
46. 46 Greenberg, P., Cox, C., LeBeau, M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:6 (1997), 2079–2088.
47. 47 Germing, U., Strupp, C., Aivado, M., Gattermann, N., New prognostic parameters for chronic myelomonocytic leukemia. [letter] Blood 100:2 (2002), 731–732 author reply 2-3.
48. 48 Kantarjian, H., O'Brien, S., Ravandi, F., et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 113:6 (2008), 1351–1361.
49. 49 Savona, M.R., Malcovati, L., Komrokji, R., et al., MDS/MPN International Working Group. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood 125:12 (2015), 1857–1865.
50. 50 Malcovati, L., Hellström-Lindberg, E., Bowen, D., et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 122:17 (2013), 2943–2964.
51. 51 Garcia-Manero, G., Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 89:1 (2014), 97–108.
52. 52 Hellström-Lindberg, E., Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 89:1 (1995), 67–71.
53. 53 Moyo, V., Lefebvre, P., Duh, M.S., Yektashenas, B., Mundle, S., Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol 87:7 (2008), 527–536.
54. 54 Jädersten, M., Montgomery, S.M., Dybedal, I., Porwit-MacDonald, A., Hellström-Lindberg, E., Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 106:3 (2005), 803–811.
55. 55 Patnaik, M.M., Tefferi, A., Refractory anemia with ring sideroblasts and RARS with thrombocytosis. Am J Hematol 90:6 (2015), 549–559.
56. 56 Prica, A., Sholzberg, M., Buckstein, R., Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials. Br J Haematol 167:5 (2014), 626–638.
57. 57 Modi, Y., Shaaban, H., Gauchan, D., Maroules, M., Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia. J Oncol Pharm Pract 21:1 (2015), 74–75.
58. 58 Valent, P., Krieger, O., Stauder, R., et al. Iron overload in myelodysplastic syndromes (MDS) –diagnosis, management, and response criteria: a proposal of the Austrian MDS platform. Eur J Clin Invest 38:3 (2008), 143–149.
59. 59 Greenberg, P.L., Rigsby, C.K., Stone, R.M., et al. NCCN Task Force: transfusion and iron overload in patients with myelodysplastic syndromes. J Natl Compr Canc Netw 7:suppl 9 (2009), S1–S16.
60. 60 Chee, C.E., Steensma, D.P., Wu, W., Hanson, C.A., Tefferi, A., Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am J Hematol 83:8 (2008), 611–613.
61. 61 Tefferi, A., Mesa, R.A., Pardanani, A., et al. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. Am J Hematol 84:5 (2009), 265–267.
62. 62 Tefferi, A., Stone, R.M., Iron chelation therapy in myelodysplastic syndrome – Cui bono?. [editorial] Leukemia, 23(8), 2009, 1373.
63. 63 Durairaj, S., Chew, S., Hyslop, A., Keenan, N., Groves, M.J., Tauro, S., Predicted costs of iron-chelators in myelodysplastic syndromes: a 10-year analysis based on actual prevalence and red cell transfusion rates. Am J Hematol 86:5 (2011), 406–410.
64. 64 Cermak, J., Jonasova, A., Vondrakova, J., et al. Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome. Hemoglobin 35:3 (2011), 217–227.
65. 65 Vichinsky, E., Clinical application of deferasirox: practical patient management. Am J Hematol 83:5 (2008), 398–402.
66. 66 Wattel, E., Guerci, A., Hecquet, B., et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia: Groupe Français des Myélodysplasies and European CMML Group. Blood 88:7 (1996), 2480–2487.
67. 67 Venditti, A., Tamburini, A., Buccisano, F., et al. A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes. Ann Hematol 79:3 (2000), 138–142.
68. 68 Cambier, N., Wattel, E., Menot, M.L., Guerci, A., Chomienne, C., Fenaux, P., All-trans retinoic acid in adult chronic myelomonocytic leukemia: results of a pilot study. Leukemia 10:7 (1996), 1164–1167.
69. 69 Beran, M., Estey, E., O'Brien, S.M., et al. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 31:5-6 (1998), 521–531.
70. 70 Beran, M., Estey, E., O'Brien, S., et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 17:9 (1999), 2819–2830.
71. 71 Quintas-Cardama, A., Kantarjian, H., O'Brien, S., et al. Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer 107:7 (2006), 1525–1529.
72. 72 Siitonen, T., Timonen, T., Juvonen, E., et al., Finnish Leukemia Group. Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes. Haematologica 92:8 (2007), 1119–1122.
73. 73 Feldman, E.J., Cortes, J., DeAngelo, D.J., et al. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia 22:9 (2008), 1707–1711.
74. 74 Padron, E., Painter, J.S., Kunigal, S., et al. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood 121:25 (2013), 5068–5077.
75. 75 Aribi, A., Borthakur, G., Ravandi, F., et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 109:4 (2007), 713–717.
76. 76 Braun, T., Itzykson, R., Renneville, A., et al. Groupe Francophone des Myélodysplasies. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood 118:14 (2011), 3824–3831.
77. 77 Costa, R., Abdulhaq, H., Haq, B., et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 117:12 (2011), 2690–2696.
78. 78 Fianchi, L., Criscuolo, M., Breccia, M., et al. High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. Leuk Lymphoma 54:3 (2013), 658–661.
79. 79 Garcia-Manero, G., Gore, S.D., Cogle, C., et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 29:18 (2011), 2521–2527.
80. 80 Thorpe, M., Montalvão, A., Pierdomenico, F., Moita, F., Almeida, A., Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review. Leuk Res 36:8 (2012), 1071–1073.
81. 81 Wijermans, P.W., Rüter, B., Baer, M.R., Slack, J.L., Saba, H.I., Lübbert, M., Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res 32:4 (2008), 587–591.
82. 82 Wong, E., Seymour, J.F., Kenealy, M., Westerman, D., Herbert, K., Dickinson, M., Treatment of chronic myelomonocytic leukemia with azacitidine. [letter] Leuk Lymphoma 54:4 (2013), 878–880.
83. 83 Patnaik, M.M., Wassie, E.A., Padron, E., et al. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. Blood Cancer J, 5, 2015, e280.
84. 84 Eissa, H., Gooley, T.A., Sorror, M.L., et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. Biol Blood Marrow Transplant 17:6 (2011), 908–915.
85. 85 Elliott, M.A., Tefferi, A., Hogan, W.J., et al. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant 37:11 (2006), 1003–1008.
86. 86 Krishnamurthy, P., Lim, Z.Y., Nagi, W., et al. Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience. Bone Marrow Transplant 45:10 (2010), 1502–1507.
87. 87 Kröger, N., Zabelina, T., Guardiola, P., et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 118:1 (2002), 67–73.
88. 88 Zhang, L., Gajewski, T.F., Kline, J., PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 114:8 (2009), 1545–1552.
89. 89 Ocheni, S., Kröger, N., Zabelina, T., Zander, A.R., Bacher, U., Outcome of allo-SCT for chronic myelomonocytic leukemia. Bone Marrow Transplant 43:8 (2009), 659–661.
90. 90 Perez Botero, J., Oliveira, J.L., Chen, D., et al. ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26. Blood Cancer J, 5, 2015, e315.
91. 91 Symeonidis, A., van Biezen, A., Mufti, G., et al. Allogeneic stem cell transplantation in patients with chronic myelomonocytic leukaemia: the impact of WHO classification and of the conditioning regimen on the transplantation outcome. Bone Marrow Transplant, 45(S241), 2010 abstract P803.
92. 92 Duong, H.K., Akhtari, M., Ahn, K.W., et al. Allogeneic hematopoietic cell transplantation for adult chronic myelomonocytic leukemia. Biol Blood Marrow Transplant 21:2, suppl (2015), S30–S31.
93. 93 Cutler, C.S., Lee, S.J., Greenberg, P., et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104:2 (2004), 579–585.
94. 94 Koreth, J., Pidala, J., Perez, W.S., et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol 31:21 (2013), 2662–2670.
95. 95 Damaj, G., Duhamel, A., Robin, M., et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies. J Clin Oncol 30:36 (2012), 4533–4540.